Joud Fahed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joud Fahed has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Azka Naeem
Division of Cardiovascular Imaging (A.N., R.P., O.K.K.), St. Francis Hospital and Heart Center, Roslyn, NY
2 shared publications - George G. Kidess
Wayne State University School of Medicine, Detroit, MI, USA
2 shared publications - Hayah Kassis-George
Division of Advance heart failure and heart transplant, Allegheny General Hospital, Pittsburgh, PA, United States of America
2 shared publications - Mohamed Chadi Alraies
Department of Cardiology Detroit Medical Center Detroit Michigan USA
2 shared publications - Muhammad Hashim Khan
Department of Internal Medicine, Maimonides Medical Centre, Brooklyn, NY, United States of America
2 shared publications - Olayiwola Bolaji
Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by Probiologists Limited in International Journal of Cardiology and Cardiovascular Diseases
- Vol. 6 (1) , 41-44
Outcomes of cardiac myosin inhibitors in hypertrophic cardiomyopathy: an updated brief meta-analysis
Obstructive hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease occurring in approximately 1 in 500 adults worldwide, characterized by left ventricular outflow tract (LVOT) obstruction, symptoms of heart failure, and increased risk of sudden cardiac death.
- 25 May 2026
- Published by Probiologists Limited in International Journal of Cardiology and Cardiovascular Diseases
- Vol. 6 (1) , 41-44
Open AccessOutcomes of cardiac myosin inhibitors in hypertrophic cardiomyopathy: an updated brief meta-analysis
Obstructive hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease occurring in approximately 1 in 500 adults worldwide, characterized by left ventricular outflow tract (LVOT) obstruction, symptoms of heart failure, and increased risk of sudden cardiac death.
- 2 January 2026
- Published by Elsevier in International Journal of Cardiology
- Vol. 447, 134150
Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up
- 2 January 2026
- Published by Elsevier in International Journal of Cardiology
- Vol. 447, 134150
Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up
- Open Access
Long-Term Clinical Outcomes of Sotatercept in Pulmonary Hypertension: A Retrospective Cohort Analysis
Background: Sotatercept, an activin receptor ligand trap, has demonstrated significant short-term hemodynamic improvements in pulmonary hypertension (PH) based on clinical trials. However, evidence regarding long-term outcomes in real-world settings remains limited. Methods: Using data from the TriNetX global federated health research network covering 102 healthcare organizations, we conducted a retrospective cohort study comparing 185 patients with PH receiving sotatercept to 212,349 PH patients not receiving sotatercept. After 1:1 propensity score matching to balance baseline characteristics, we assessed outcomes at 6 months, 1 year, 3 years, and 5 years post-initiation and cox proportional hazards was used. Primary outcomes included all-cause mortality, rehospitalization rates, major adverse cardiovascular events (MACE), and BNP elevation (≥100 pg/mL). Results: Over 5 years of follow-up, sotatercept treatment was associated with significantly lower all-cause mortality (5.4% vs. 27.3%; risk difference, -21.9 percentage points [95% CI, -29.1 to -14.7]; p<0.001; hazard ratio [HR], 0.40 [95% CI, 0.16-0.99]). Rehospitalization rates were also substantially reduced in the sotatercept group (15.4% vs. 38.1%; risk difference, -22.8 percentage points [95% CI, - 35.8 to -9.7]; p=0.002; HR, 0.12 [95% CI, 0.03-0.49]). MACE occurrence was significantly lower with sotatercept (6.4% vs. 15.5%; risk difference, -9.1 percentage points [95% CI, -16.2 to -2.0]; p=0.011; HR, 0.45 [95% CI, 0.14-1.41]), while BNP elevation showed no significant difference (12.8% vs. 10.6%; p=0.626). Treatment benefits were observed as early as 6 months post-initiation, progressively increasing magnitude through 5 years of follow-up. Sensitivity analyses using alternative matching methods and instrumental variable approaches confirmed the robustness of these findings. Conclusions: In this large real-world cohort study with long-term follow-up, sotatercept was associated with substantial reductions in mortality, rehospitalization, and cardiovascular events in patients with pulmonary hypertension. These benefits increased over time, suggesting potential disease-modifying effects beyond acute hemodynamic improvements. These findings complement data from randomized controlled trials and support the role of sotatercept in improving long-term outcomes in pulmonary hypertension.
Open AccessLong-Term Clinical Outcomes of Sotatercept in Pulmonary Hypertension: A Retrospective Cohort Analysis
Background: Sotatercept, an activin receptor ligand trap, has demonstrated significant short-term hemodynamic improvements in pulmonary hypertension (PH) based on clinical trials. However, evidence regarding long-term outcomes in real-world settings remains limited. Methods: Using data from the TriNetX global federated health research network covering 102 healthcare organizations, we conducted a retrospective cohort study comparing 185 patients with PH receiving sotatercept to 212,349 PH patients not receiving sotatercept. After 1:1 propensity score matching to balance baseline characteristics, we assessed outcomes at 6 months, 1 year, 3 years, and 5 years post-initiation and cox proportional hazards was used. Primary outcomes included all-cause mortality, rehospitalization rates, major adverse cardiovascular events (MACE), and BNP elevation (≥100 pg/mL). Results: Over 5 years of follow-up, sotatercept treatment was associated with significantly lower all-cause mortality (5.4% vs. 27.3%; risk difference, -21.9 percentage points [95% CI, -29.1 to -14.7]; p<0.001; hazard ratio [HR], 0.40 [95% CI, 0.16-0.99]). Rehospitalization rates were also substantially reduced in the sotatercept group (15.4% vs. 38.1%; risk difference, -22.8 percentage points [95% CI, - 35.8 to -9.7]; p=0.002; HR, 0.12 [95% CI, 0.03-0.49]). MACE occurrence was significantly lower with sotatercept (6.4% vs. 15.5%; risk difference, -9.1 percentage points [95% CI, -16.2 to -2.0]; p=0.011; HR, 0.45 [95% CI, 0.14-1.41]), while BNP elevation showed no significant difference (12.8% vs. 10.6%; p=0.626). Treatment benefits were observed as early as 6 months post-initiation, progressively increasing magnitude through 5 years of follow-up. Sensitivity analyses using alternative matching methods and instrumental variable approaches confirmed the robustness of these findings. Conclusions: In this large real-world cohort study with long-term follow-up, sotatercept was associated with substantial reductions in mortality, rehospitalization, and cardiovascular events in patients with pulmonary hypertension. These benefits increased over time, suggesting potential disease-modifying effects beyond acute hemodynamic improvements. These findings complement data from randomized controlled trials and support the role of sotatercept in improving long-term outcomes in pulmonary hypertension.
- Open Access
- 10 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e83846
Transcatheter Aortic Valve Replacement (TAVR)-Induced Hemodynamically Unstable Supraventricular Tachycardia in an Elderly Patient With a Complex Cardiovascular History
Transcatheter aortic valve replacement (TAVR) is an important alternative to surgical aortic valve replacement (SAVR) as it reduces stay length and complication rates. Despite this apparent advantage, clinicians must still be aware of these complications. In this paper, we present a case of an elderly female who had an ICD placed years before presentation, presenting with wide complex tachycardia weeks after the TAVR procedure. In this case, the differentiation between ventricular tachycardia and supraventricular tachycardia with aberrancy proved to be a diagnostic challenge. This case highlights an arrhythmia-related complication stemming from TAVR and the utility of the Implantable cardioverter defibrillator (ICD) as an important diagnostic tool in differentiating these rhythms and confirming the temporal relationship between this arrhythmia and the valve replacement procedure.
- 10 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e83846
Open AccessTranscatheter Aortic Valve Replacement (TAVR)-Induced Hemodynamically Unstable Supraventricular Tachycardia in an Elderly Patient With a Complex Cardiovascular History
Transcatheter aortic valve replacement (TAVR) is an important alternative to surgical aortic valve replacement (SAVR) as it reduces stay length and complication rates. Despite this apparent advantage, clinicians must still be aware of these complications. In this paper, we present a case of an elderly female who had an ICD placed years before presentation, presenting with wide complex tachycardia weeks after the TAVR procedure. In this case, the differentiation between ventricular tachycardia and supraventricular tachycardia with aberrancy proved to be a diagnostic challenge. This case highlights an arrhythmia-related complication stemming from TAVR and the utility of the Implantable cardioverter defibrillator (ICD) as an important diagnostic tool in differentiating these rhythms and confirming the temporal relationship between this arrhythmia and the valve replacement procedure.
- Open Access
- 4 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5649-5652
A potential protective role of congenital peritoneal encapsulation coexisting with metastatic colon cancer: a rare case report
Introduction and importance: Congenital peritoneal encapsulation (CPE) is a rare condition in which the small intestine is encased within a mesothelial-lined sac. The following case is an extremely rare description of the co-existence of both colon cancer and peritoneal encapsulation, highlighting the potential role of this co-existence in preventing the spread of metastases and tumor implantation. Case-presentation: A 60-year-old female was diagnosed with metastatic colon cancer. During the operation, a thin fibrous membrane was found covering the small intestine, which suggested CPE. The tumor was removed, and the additional membrane was totally excised. The patient is currently receiving chemotherapy for metastatic treatment and is in good health. Clinical discussion: CPE is a medical condition that results from abnormal peritoneal development, and it is often confused with other differential diagnoses resulting from inflammatory causes. It can occur at different ages and remains asymptomatic for the majority of cases. However, it can be a potential cause of bowel obstruction. An intraoperative diagnosis can easily differentiate the case. The co-existence with colon cancer has been described only once in the literature. Conclusion: Peritoneal encapsulation is a rare, mostly asymptomatic condition. However, it may play a protective role in preventing metastatic colon cancer from affecting the small intestine, thus potentially opening up new avenues for the treatment of cancer metastases.
- 4 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5649-5652
Open AccessA potential protective role of congenital peritoneal encapsulation coexisting with metastatic colon cancer: a rare case report
Introduction and importance: Congenital peritoneal encapsulation (CPE) is a rare condition in which the small intestine is encased within a mesothelial-lined sac. The following case is an extremely rare description of the co-existence of both colon cancer and peritoneal encapsulation, highlighting the potential role of this co-existence in preventing the spread of metastases and tumor implantation. Case-presentation: A 60-year-old female was diagnosed with metastatic colon cancer. During the operation, a thin fibrous membrane was found covering the small intestine, which suggested CPE. The tumor was removed, and the additional membrane was totally excised. The patient is currently receiving chemotherapy for metastatic treatment and is in good health. Clinical discussion: CPE is a medical condition that results from abnormal peritoneal development, and it is often confused with other differential diagnoses resulting from inflammatory causes. It can occur at different ages and remains asymptomatic for the majority of cases. However, it can be a potential cause of bowel obstruction. An intraoperative diagnosis can easily differentiate the case. The co-existence with colon cancer has been described only once in the literature. Conclusion: Peritoneal encapsulation is a rare, mostly asymptomatic condition. However, it may play a protective role in preventing metastatic colon cancer from affecting the small intestine, thus potentially opening up new avenues for the treatment of cancer metastases.